|
1
|
Crazzolara R and Bendall L: Emerging
treatments in acute lymphoblastic leukemia. Curr Cancer Drug
Targets. 9:19–31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pérez-Saldivar ML, Fajardo-Gutiérrez A,
Bernáldez-Ríos R, Martínez-Avalos A, Medina-Sanson A,
Espinosa-Hernández L, Jde Flores-Chapa D, Amador-Sánchez R,
Peñaloza-González JG, Alvarez-Rodríguez FJ, et al: Childhood acute
leukemias are frequent in Mexico City: Descriptive epidemiology.
BMC Cancer. 11:3552011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gonen N and Assaraf YG: Antifolates in
cancer therapy: Structure, activity and mechanisms of drug
resistance. Drug Resist Updat. 15:183–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bonadonna G, Valagussa P, Moliterni A,
Zambetti M and Brambilla C: Adjuvant cyclophosphamide,
methotrexate, and fluorouracil in node-positive breast Cancer: The
results of 20 years of follow-up. N Engl J Med. 332:901–906. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guardiola E, Peyrade F, Chaigneau L,
Cupissol D, Tchiknavorian X, Bompas E, Madroszyk A, Ronchin P,
Schneider M, Bleuze JP, et al: Results of a randomised phase II
study comparing docetaxel with methotrexate in patients with
recurrent head and neck cancer. Eur J Cancer. 40:2071–2076. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fuchs N, Bielack SS, Epler D, Bieling P,
Delling G, Körholz D, Graf N, Heise U, Jürgens H, Kotz R, et al:
Long-term results of the co-operative German-Austrian-Swiss
osteosarcoma study group's protocol COSS-86 of intensive multidrug
chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol.
9:893–899. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Visentin M, Zhao R and Goldman ID: The
Antifolates. Hematol Oncol Clin North Am. 26(629–648): ix2012.
|
|
9
|
Gorlick R, Goker E, Trippett T, Waltham M,
Banerjee D and Bertino JR: Intrinsic and acquired resistance to
methotrexate in acute leukemia. N Engl J Med. 335:1041–1048. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Jonge R, Tissing WJ, Hooijberg JH, et
al: Polymorphisms in folate-related genes and risk of pediatric
acute lymphoblastic leukemia. Blood. 113:2284–2289. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Assaraf YG: Molecular basis of antifolate
resistance. Cancer Metastasis Rev. 26:153–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bertino JR, Göker E, Gorlick R, Li WW and
Banerjee D: Resistance mechanisms to methotrexate in tumors. Stem
Cells. 14:5–9. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matherly LH, Taub JW, Wong SC, Simpson PM,
Ekizian R, Buck S, Williamson M, Amylon M, Pullen J, Camitta B and
Ravindranath Y: Increased frequency of expression of elevated
dihydrofolate reductase in T-cell versus B-precursor acute
lymphoblastic leukemia in children. Blood. 90:578–589.
1997.PubMed/NCBI
|
|
14
|
Chauhan PS, Bhushan B, Singh LC, Mishra
AK, Saluja S, Mittal V, Gupta DK and Kapur S: Expression of genes
related to multiple drug resistance and apoptosis in acute
leukemia: Response to induction chemotherapy. Exp Mol Pathol.
92:44–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dulucq S, St-Onge G, Gagné V, Ansari M,
Sinnett D, Labuda D, Moghrabi A and Krajinovic M: DNA variants in
the dihydrofolate reductase gene and outcome in childhood ALL.
Blood. 111:3692–3700. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the
Classification of the Acute Leukaemias French-American-British
(FAB) Co-operative Group. Br J Haematol. 33:451–458. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008
revision of the World health organization (WHO) classification of
myeloid neoplasms and acute leukemia: Rationale and important
changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gómez-Gómez Y, Organista-Nava J,
Saavedra-Herrera MV, Rivera-Ramírez AB, Terán-Porcayo MA, Del
Carmen Alarcón-Romero L, Illades-Aguiar B and Leyva-Vázquez MA:
Survival and risk of relapse of acute lymphoblastic leukemia in a
Mexican population is affected by dihydrofolate reductase gene
polymorphisms. Exp Ther Med. 3:665–672. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nolan T, Hands RE and Bustin SA:
Quantification of mRNA using real-time RT-PCR. Nat Protoc.
1:1559–1582. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Organista-Nava J, Gómez-Gómez Y,
Illades-Aguiar B, Del Carmen Alarcón-Romero L, Saavedra-Herrera MV,
Rivera-Ramírez AB, Garzón-Barrientos VH and Leyva-Vázquez MA: High
miR-24 expression is associated with risk of relapse and poor
survival in acute leukemia. Oncol Rep. 33:1639–1649. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matheson EC, Hogarth LA, Case MC, Irving
JA and Hall AG: DHFR and MSH3 co-amplification in childhood acute
lymphoblastic leukaemia, in vitro and in vivo. Carcinogenesis.
28:1341–1346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abali EE, Skacel NE, Celikkaya H and Hsieh
YC: Regulation of human dihydrofolate reductase activity and
expression. Vitam Horm. 79:267–292. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Galbiatti AL, Castro R, Caldas HC,
Padovani JA Jr, Pavarino ÉC and Goloni-Bertollo EM: Alterations in
the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes
after treatment of laryngeal cancer cells with high and low doses
of methotrexate. Tumor Biol. 34:3765–3771. 2013. View Article : Google Scholar
|
|
24
|
Ng SM, Lin HP, Ariffin WA, Zainab AK, Lam
SK and Chan LL: Age, sex, haemoglobin level, and white cell count
at diagnosis are important prognostic factors in children with
acute lymphoblastic leukemia treated with BFM-type protocol. J Trop
Pediatr. 46:338–343. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Smith M, Arthur D, Camitta B, Carroll AJ,
Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, et al:
Uniform approach to risk classification and treatment assignment
for children with acute lymphoblastic leukemia. J Clin Oncol.
14:18–24. 1996. View Article : Google Scholar : PubMed/NCBI
|
